Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction
- 16 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (7) , 882-889
Abstract
Aims: Glucagon-like peptide 1 (GLP-1) is a gut incretin hormone inducing post-prandial insulin secretion. Glucagon-like peptide 1 levels were recently found to be increased in patients with acute myocardial infarction. Glucagon-like peptide 1 receptor agonists improve cardiovascular outcomes in patients with diabetes. The aim of this study was to assess the predictive capacity of GLP-1 serum levels for cardiovascular outcome in patients with myocardial infarction. Methods and results: In 918 patients presenting with myocardial infarction [321 ST-segment elevation myocardial infarction and 597 non-ST-segment elevation myocardial infarction (NSTEMI)] total GLP-1, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and the Global Registry of Acute Coronary Events (GRACE) score were assessed at time of hospital admission. The primary composite outcome of the study was the first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Kaplan–Meier survival plots and univariable Cox regression analyses found GLP-1 to be associated with adverse outcome [hazard ratio (HR) of logarithmized GLP-1 values: 6.29, 95% confidence interval (CI): 2.67–14.81; P < 0.0001]. After further adjustment for age, sex, family history of cardiovascular disease, smoking, diabetes, hypertension, hypercholesterinaemia, glomerular filtration rate (GFR) CKD-EPI, hs-CRP, hs-Troponin T, and NT-proBNP levels the HR remained significant at 10.98 (95% CI: 2.63–45.90; P = 0.0010). Time-dependent receiver operating characteristic curve analyses illustrated that GLP-1 levels are a strong indicator for early events. For events up to 30 days after admission, GLP-1 proved to be superior to other biomarkers including hs-Troponin T, GFR CKD-EPI, hs-CRP, and NT-proBNP. Adjustment of the GRACE risk estimate by addition of GLP-1 increased the area under the receiver operating characteristic curve over time in NSTEMI patients. Conclusion: In patients hospitalized for myocardial infarction, GLP-1 levels are associated with cardiovascular events.Keywords
Funding Information
- Else Kröner-Fresenius Foundation and the German Society for Cardiology
- Deutsche Forschungsgemeinschaft (SFB TRR 219 M-03)
- Marga und Walter Boll-Stiftung
- Deutsche Forschungsgemeinschaft (SFB TRR 219 M-03 and M-05)
This publication has 33 references indexed in Scilit:
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialThe Lancet, 2018
- Myocardial infarction is sufficient to increase GLP‐1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacityDiabetes, Obesity and Metabolism, 2018
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1Cell Metabolism, 2018
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationEuropean Heart Journal, 2015
- New antidiabetic therapiesCurrent Opinion in Lipidology, 2012
- Evaluating Prediction Rules fort-Year Survivors With Censored Regression ModelsJournal of the American Statistical Association, 2007
- Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)BMJ, 2006
- The TIMI Risk Score for Unstable Angina/Non–ST Elevation MIJAMA, 2000